ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
21 hedge funds and large institutions have $18.3M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
14% more capital invested
Capital invested by funds: $16.1M → $18.3M (+$2.18M)
2.34% more ownership
Funds ownership: 35.94% → 38.28% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 22 → 21 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
+$1.08M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$473K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$451K |
| 4 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$247K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$597K |
| 2 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
-$367K |
| 3 |
Jane Street
New York
|
-$347K |
| 4 |
LWPC
Legacy Wealth Partners (California)
Calabasas,
California
|
-$121K |
| 5 |
BAMG
Brand Asset Management Group
Chesterfield,
Missouri
|
-$29K |
CNCR Hedge Fund Activity: Q2 2021 in Review
21 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q2 2021, worth a combined $18.3M — up 14% from $16.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CNCR and 4 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 8 added.
The largest buyer was Flow Traders U.S., opening a new position worth an estimated $1.08M. The largest seller was Goldman Sachs, exiting entirely with an estimated $597K sold.
- 21 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q2 2021, down from 22 in Q1 2021.
- Funds reported $18.3M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q2 2021, up 14% quarter-over-quarter.
- 4 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q2 2021 and 5 closed out, a net change of -1 holder.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q2 2021 was Flow Traders U.S., an estimated $1.08M added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q2 2021 was Goldman Sachs, an estimated $597K sold.
Based on aggregated 13F filings for Q2 2021.